LOS ANGELES, CA / ACCESSWIRE / September 22, 2020 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Virtual Panel, titled, "The Pursuit of Molluscum: Beetlejuice and Nobel Prizes", hosted by John Vandermosten, Senior Biotech Analyst at Zack's Small Cap Research. Joining him on the panel are:
Paul Brown Stafford, Chairman and CEO of Novan Inc. (NASDAQ:NOVN)
Ted White, CEO and President of Verrica Pharmaceuticals (NASDAQ:VRCA)
Click the following link to watch the Video Interview:
VIRTUAL PANEL - The Pursuit of Molluscum: Beetlejuice and Nobel Prizes
You can follow SNN Network on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE
Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer
About Novan Inc.
Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging its proprietary nitric oxide (NO) based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCE's) to treat multiple indications in dermatology, men's and women's health, infectious diseases and gastroenterology conditions with significant unmet needs. The Company's lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would address an important patient-care need for the treatment of molluscum. For more information about Novan Inc., please visit: www.Novan.com
About Verrica Pharmaceuticals
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. The Company's late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. A Complete Response Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and is currently conducting a Phase 2 study of VP-102 for the treatment of external genital warts. The Company is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. For more information, visit www.verrica.com.
About SNN Network
SNN Network is an investor portal covering the Small-, Micro- and Nano-cap markets by providing news, insights, education tools and expert commentary. Subscribe now to our YouTube Channel to be notified when new CEO video interviews, Wall Street Views with investing experts, and Planet MicroCap Podcast episodes are available.
Subscribe NOW to SNN Network: http://bit.ly/1Q5Yfym
SNN Network
info@snnwire.com
SOURCE: Stock News Now
View source version on accesswire.com:
https://www.accesswire.com/607200/Novan-Inc-and-Verrica-Pharmaceuticals-Participate-in-Virtual-Panel-to-Discuss-Developing-Treatments-for-Molluscum-Contagiosum-on-SNN-Network
